IL12/23 Blockade for Refractory Immune-Mediated Colitis: 2-Center Experience

Anusha Shirwaikar Thomas; Seung Eun Lee; Malek Shatila; Enrico N. De Toni; Helga Paula Török; Najib Ben Khaled; Nicholas Powell; Ryan Weight; David M. Faleck; Yinghong Wang

doi:10.14309/ajg.0000000000002332

IL12/23 Blockade for Refractory Immune-Mediated Colitis: 2-Center Experience

Anusha Shirwaikar Thomas, Seung Eun Lee, Malek Shatila, Enrico N. De Toni, Helga Paula Török, Najib Ben Khaled, Nicholas Powell, Ryan Weight, David M. Faleck, Yinghong Wang

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

INTRODUCTION:Immune checkpoint inhibitor-mediated colitis (IMC) is commonly managed with steroids and biologics. We evaluated the efficacy of ustekinumab (UST) in treating IMC refractory to steroids plus infliximab and/or vedolizumab.RESULTS:Nineteen patients were treated with UST for IMC refractory to steroids plus infliximab (57.9%) and/or vedolizumab (94.7%). Most of them had grade ≥3 diarrhea (84.2%), and colitis with ulceration was present in 42.1%. Thirteen patients (68.4%) attained clinical remission with UST, and mean fecal calprotectin levels dropped significantly after treatment (629 ± 101.5 mcg/mg to 92.0 ± 21.7 mcg/mg, P = 0.0004).DISCUSSION:UST is a promising therapy for the treatment of refractory IMC.

Original language	English
Pages (from-to)	1679-1683
Number of pages	5
Journal	American Journal of Gastroenterology
Volume	118
Issue number	9
DOIs	https://doi.org/10.14309/ajg.0000000000002332
State	Published - 1 Sep 2023
Externally published	Yes

Keywords

cancer
immune checkpoint inhibitor
immune-mediated colitis
refractory
toxicity
ustekinumab

Access to Document

10.14309/ajg.0000000000002332

Cite this

@article{0d7630fdd5bc4f10b890b10055019e40,

title = "IL12/23 Blockade for Refractory Immune-Mediated Colitis: 2-Center Experience",

abstract = "INTRODUCTION:Immune checkpoint inhibitor-mediated colitis (IMC) is commonly managed with steroids and biologics. We evaluated the efficacy of ustekinumab (UST) in treating IMC refractory to steroids plus infliximab and/or vedolizumab.RESULTS:Nineteen patients were treated with UST for IMC refractory to steroids plus infliximab (57.9\%) and/or vedolizumab (94.7\%). Most of them had grade ≥3 diarrhea (84.2\%), and colitis with ulceration was present in 42.1\%. Thirteen patients (68.4\%) attained clinical remission with UST, and mean fecal calprotectin levels dropped significantly after treatment (629 ± 101.5 mcg/mg to 92.0 ± 21.7 mcg/mg, P = 0.0004).DISCUSSION:UST is a promising therapy for the treatment of refractory IMC.",

keywords = "cancer, immune checkpoint inhibitor, immune-mediated colitis, refractory, toxicity, ustekinumab",

author = "\{Shirwaikar Thomas\}, Anusha and Lee, \{Seung Eun\} and Malek Shatila and \{De Toni\}, \{Enrico N.\} and T{\"o}r{\"o}k, \{Helga Paula\} and \{Ben Khaled\}, Najib and Nicholas Powell and Ryan Weight and Faleck, \{David M.\} and Yinghong Wang",

year = "2023",

month = sep,

day = "1",

doi = "10.14309/ajg.0000000000002332",

language = "English",

volume = "118",

pages = "1679--1683",

journal = "American Journal of Gastroenterology",

issn = "0002-9270",

publisher = "Wolters Kluwer Health",

number = "9",

}

TY - JOUR

T1 - IL12/23 Blockade for Refractory Immune-Mediated Colitis

T2 - 2-Center Experience

AU - Shirwaikar Thomas, Anusha

AU - Lee, Seung Eun

AU - Shatila, Malek

AU - De Toni, Enrico N.

AU - Török, Helga Paula

AU - Ben Khaled, Najib

AU - Powell, Nicholas

AU - Weight, Ryan

AU - Faleck, David M.

AU - Wang, Yinghong

PY - 2023/9/1

Y1 - 2023/9/1

N2 - INTRODUCTION:Immune checkpoint inhibitor-mediated colitis (IMC) is commonly managed with steroids and biologics. We evaluated the efficacy of ustekinumab (UST) in treating IMC refractory to steroids plus infliximab and/or vedolizumab.RESULTS:Nineteen patients were treated with UST for IMC refractory to steroids plus infliximab (57.9%) and/or vedolizumab (94.7%). Most of them had grade ≥3 diarrhea (84.2%), and colitis with ulceration was present in 42.1%. Thirteen patients (68.4%) attained clinical remission with UST, and mean fecal calprotectin levels dropped significantly after treatment (629 ± 101.5 mcg/mg to 92.0 ± 21.7 mcg/mg, P = 0.0004).DISCUSSION:UST is a promising therapy for the treatment of refractory IMC.

AB - INTRODUCTION:Immune checkpoint inhibitor-mediated colitis (IMC) is commonly managed with steroids and biologics. We evaluated the efficacy of ustekinumab (UST) in treating IMC refractory to steroids plus infliximab and/or vedolizumab.RESULTS:Nineteen patients were treated with UST for IMC refractory to steroids plus infliximab (57.9%) and/or vedolizumab (94.7%). Most of them had grade ≥3 diarrhea (84.2%), and colitis with ulceration was present in 42.1%. Thirteen patients (68.4%) attained clinical remission with UST, and mean fecal calprotectin levels dropped significantly after treatment (629 ± 101.5 mcg/mg to 92.0 ± 21.7 mcg/mg, P = 0.0004).DISCUSSION:UST is a promising therapy for the treatment of refractory IMC.

KW - cancer

KW - immune checkpoint inhibitor

KW - immune-mediated colitis

KW - refractory

KW - toxicity

KW - ustekinumab

UR - https://www.scopus.com/pages/publications/85169183094

U2 - 10.14309/ajg.0000000000002332

DO - 10.14309/ajg.0000000000002332

M3 - Article

C2 - 37216614

AN - SCOPUS:85169183094

SN - 0002-9270

VL - 118

SP - 1679

EP - 1683

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

IS - 9

ER -

IL12/23 Blockade for Refractory Immune-Mediated Colitis: 2-Center Experience

Abstract

Keywords

Access to Document

Fingerprint

Cite this